Abstract
Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor “Triplet” Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have